Key terms
About URGN
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest URGN news
Apr 18
6:15am ET
Buy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference Presentations
Apr 15
8:07am ET
UroGen Pharma announces FDA acceptance of UGM-103 IND
Apr 09
7:40am ET
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
Apr 04
6:25am ET
Urogen Pharma’s Strategic Defense and Pipeline Progress Bolster Buy Rating
Apr 03
8:02am ET
UroGen Pharma files patent infringement action against Teva Pharmaceuticals
Mar 18
6:30am ET
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)
Mar 15
7:52am ET
UroGen Pharma price target lowered to $34 from $35 at Oppenheimer
Mar 14
3:40pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM)
Mar 14
1:05pm ET
TD Cowen Sticks to Their Buy Rating for Urogen Pharma (URGN)
Mar 01
7:12am ET
Teva Challenges UroGen Pharma’s Jelmyto Patent Rights
Feb 08
4:47am ET
UroGen Pharma Shares Insights at Guggenheim Healthcare Talks
Jan 24
8:34am ET
UroGen Pharma price target raised to $35 from $32 at Oppenheimer
Jan 24
8:15am ET
UroGen initiates submission of rolling NDA to FDA for UGN-102
Jan 24
8:11am ET
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Urogen Pharma (URGN)
Jan 22
2:40pm ET
Analysts Offer Insights on Healthcare Companies: SurModics (SRDX), Urogen Pharma (URGN) and Blueprint Medicines (BPMC)
No recent press releases are available for URGN
URGN Financials
Key terms
Ad Feedback
URGN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
URGN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range